Biothera Pharmaceuticals is partnering with leaders in cancer immunotherapy to advance its unique technology and develop next generation immunotherapies.

Merck, a global health care leader for 125 years, is translating breakthrough science into innovative oncology medicines to help people with cancer worldwide.  

Biothera and Merck have multiple clinical trial collaborations to evaluate the safety and efficacy of Imprime PGG and KEYTRUDA® (Merck’s anti-PD-1 checkpoint inhibitor) in patients with advanced melanoma, metastatic triple negative breast cancer or head and neck squamous cell cancer.

The Big Ten cancer centers are transforming cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities.

The Big Ten Cancer Research Consortium is conducting a Phase 1b/2 study in second line non-small cell lung cancer with KEYTRUDA and Imprime PGG, under separate collaboration agreements with Merck and Biothera. 

Dana-Farber Cancer Institute is committed to providing expert, compassionate care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases.

Dana-Farber Cancer Institute is conducting a Phase 2 clinical trial of Rituxan® (rituximab) and Imprime PGG in relapsed indolent B cell non-Hodgkin lymphoma.

Eli Lilly and Company oncology research is focused in three key areas—tumor cell signaling, microenvironment, and immuno-oncology—and exploring different combinations and sequencing of therapy to help advance treatment for more people.

Biothera and Lilly have a collaborative research agreement to evaluate in preclinical models the combination of Imprime PGG and Lilly’s anti-angiogenic therapy, Cyramza® (ramucirumab).

In addition, Biothera has preclinical research agreements with The Mayo Clinic, Johns Hopkins School of Medicine and the Wistar Institute to study the mechanism of Imprime PGG and its ability to enhance anti-cancer immune responses.




Interested in partnering with Biothera?  We are actively exploring new partnership opportunities focused on enabling technologies and capabilities designed to bring life-saving therapies to patients. Please visit contact us.